Calcipotriene Scalp Solution Recalled Due to Defective Delivery System
Akorn, Inc. is recalling Calcipotriene Topical Solution 0.005% (Scalp Solution) nationwide due to a defective delivery system that could prevent the product from dispensing properly.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for a defective delivery system with no reported illnesses, injuries, or hospitalizations. The hazard is functional—the product may not dispense as intended—without evidence of actual patient harm.
Plain-English summary
Akorn, Inc. is recalling Calcipotriene Topical Solution, 0.005% (Scalp Solution) due to a defective delivery system. The recalled product is a prescription topical medication distributed nationwide in the United States, supplied in 60 mL (2 fl. oz.) bottles manufactured by HI-TECH PHARMACAL CO., INC., Amityville, N.Y.
The defect could prevent the product from dispensing as intended. The affected lot number is 378440 with an expiration date of 07/31/2023, and approximately 2,736 bottles have been distributed.
The recalled product
- Product
- Calcipotriene Topical Solution, 0.005% (Scalp Solution), Rx only, 60 mL (2 fl. oz.) bottle, Manufactured by: HI-TECH PHARMACAL CO., INC., Amityville, N.Y. 11701. NDC: 50383-732-02
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Topical / Scalp Solution
- Hazard
- dispensing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 378440
- Exp. 07/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27